文献速递内脏/肾动脉与血管畸形

急性和慢性肠系膜缺血的当代管理:来自多医院医疗系统的10年经验

Contemporary management of acute and chronic mesenteric ischemia: 10-year experience from a multihospital healthcare system.
PubMed 文献 · J Vasc Surg · 2021-11-14

该多医院医疗系统10年经验纳入407例肠系膜缺血患者(急性148例、慢性259例),急性组30天死亡率为31%,开放手术与较低的肠切除率相关(OR 0.23,95%CI 0.13-0.61)。慢性组腔内治疗的症状复发率高于旁路手术(29% vs 13%)且复发更快(64天 vs 338天)。作者认为急性肠系膜缺血开放手术仍为参考标准,慢性肠系膜缺血应以腔内优先并密切监测。

要点

  • 急性肠系膜缺血30天死亡率为31%,开放手术与较低肠切除率相关(OR 0.23,95%CI 0.13-0.61)。
  • 慢性肠系膜缺血腔内治疗症状复发率29% vs 旁路手术13%,复发更快(64天 vs 338天)。
  • 慢性肠系膜缺血开放手术(OR 3.03,95%CI 1.14-8.05)和慢性肾脏病(OR 2.37,95%CI 1.31-4.31)与主要不良事件发生率较高相关。

核心结论

  • 急性肠系膜缺血尽管血运重建技术不断进展,仍是一种高并发症和高死亡的疾病。
  • 作者认为开放手术应继续作为急性肠系膜缺血的参考标准,因为其降低肠切除的可能性。
  • 对于慢性肠系膜缺血,腔内干预改善了术后并发症,但也导致早期症状复发和再干预。
  • 作者认为腔内优先策略应作为慢性肠系膜缺血的标准治疗,并密切监测。

研究设计与样本

  • 回顾性队列研究,回顾2010年至2020年在一家多中心医院系统因急性和慢性肠系膜缺血接受血运重建的所有患者的住院和随访记录。
  • 共纳入407例患者,其中急性肠系膜缺血148例,慢性肠系膜缺血259例。
  • 采用Cox回归评估通畅率和死亡率,以Kaplan-Meier曲线可视化并用log-rank检验比较。
  • 采用Fine-Gray回归以死亡作为竞争风险进一步评估通畅率。
  • 采用logistic回归评估术后主要不良事件和30天死亡率。

主要发现

  • 急性肠系膜缺血组30天死亡率为31%。
  • 急性肠系膜缺血组开放手术与较低的肠切除率相关(OR 0.23,95%CI 0.13-0.61)。
  • 急性肠系膜缺血病因未改变结局(OR 1.30,95%CI 0.77-2.19)。
  • 急性肠系膜缺血校正分析显示糖尿病史(OR 2.77,95%CI 1.37-5.61)和就诊时脓毒症(OR 2.32,95%CI 1.18-4.58)与30天主要不良事件风险增加独立相关。
  • 慢性肠系膜缺血组开放手术(OR 3.03,95%CI 1.14-8.05)和慢性肾脏病(OR 2.37,95%CI 1.31-4.31)与主要不良事件发生率较高相关;慢性肾脏病(OR 3.02,95%CI 1.10-8.37)和血运重建前住院状态(OR 2.78,95%CI 1.01-7.61)与30天死亡率增加相关。

临床怎么用

  • 作者认为开放手术应继续作为急性肠系膜缺血的参考标准,因为其降低肠切除的可能性。
  • 作者认为腔内优先策略应作为慢性肠系膜缺血的标准治疗,并密切监测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Endovascular and hybrid methods have been increasingly used to treat mesenteric ischemia. However, the long-term outcomes and risk of symptom recurrence remain unknown. The objective of the present study was to define the predictors of postoperative morbidity, mortality, and patency loss for acute mesenteric ischemia (AMI) and chronic mesenteric ischemia (CMI). METHODS: The inpatient and follow-up records for all patients who had undergone revascularization for AMI and CMI from 2010 to 2020 at a multicenter hospital system were reviewed. Patency and mortality were evaluated with Cox regression, visualized with Kaplan-Meier curves, and compared using log-rank testing. Patency was further evaluated using Fine-Gray regression with death as a competing risk. The postoperative major adverse events (MAE) and 30-day mortality were evaluated with logistic regression. RESULTS: A total of 407 patients were included, 148 with AMI and 259 with CMI. For the AMI group, the 30-day mortality was 31%. Open surgery was associated with lower rates of bowel resection (odds ratio [OR], 0.23; 95% confidence interval [CI], 0.13-0.61). The etiology of AMI also did not change the outcomes (OR, 1.30; 95% CI, 0.77-2.19). Adjusted analyses indicated that a history of diabetes (OR, 2.77; 95% CI, 1.37-5.61) and sepsis on presentation (OR, 2.32; 95% CI, 1.18-4.58) were independently associated with an increased risk of 30-day MAE. In the CMI group, open surgery and chronic kidney disease were associated with a higher incidence of MAE (OR, 3.03; 95% CI, 1.14-8.05; OR, 2.37; 95% CI, 1.31-4.31). In contrast, chronic kidney disease (OR, 3.02; 95% CI, 1.10-8.37) and inpatient status before revascularization (OR, 2.78; 95% CI, 1.01-7.61) were associated with increased 30-day mortality. For the CMI group, the endovascular cohort had experienced greater rates of symptom recurrence (29% vs 13%) with a faster onset (endovascular, 64 days; vs bypass, 338 days). CONCLUSIONS: AMI remains a morbid disease despite the evolving revascularization techniques. An open approach should remain the reference standard because it reduces the likelihood of bowel resection. For CMI, endovascular interventions have improved the postoperative morbidity but have also resulted in early symptom recurrence and reintervention. An endovascular-first approach should be the standard of care for CMI with close surveillance.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Andraska EA, Tran LM, Haga LM, et al. Contemporary management of acute and chronic mesenteric ischemia: 10-year experience from a multihospital healthcare system. J Vasc Surg. 2021. PMID: 34788652. doi:10.1016/j.jvs.2021.11.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。